Eli Lilly skyrockets following positive Alzheimer's data

Positive results from phase II trial with drug against Alzheimer's disease, an area also occupying Novo Nordisk, cause Eli Lilly's share price to soar.

Photo: Mike Blake/Reuters/Ritzau Scanpix

US pharmaceutical firm Eli Lilly has a 14.2-percent higher indication in the premarket after the company's drug donanemab reached its primary endpoint in a phase II trial with patients against early symptomatic Alzheimer's disease, according to Bloomberg News.

The substance donanemab, which is an antibody that targets a type of beta amyloid, reached its endpoint, according to Eli Lilly.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs